Neoadjuvant immune checkpoint inhibitors for localized dMMR/MSI-H gastric cancer: a meta-analysis
Neoadjuvant ICIs are associated with favorable efficacy and safety in localized dMMR/MSI-H gastric and GEJ cancers. Longer neoadjuvant exposure (≥3 months) may improve pCR rates. Larger prospective studies are needed to define optimal treatment duration and the role of organ-preserving strategies such as NOM.
Authors
- Usón Pls
- M.B. Sonbol
- K. Chung
- R.A. Pereira
- C. de la Fouchardière
- G. Lenz
- M. Tumelero
- T. Bekaii-Saab
- I. Michelon
- W.K. Schwengber
- L.F. Leite da Silva
Institutions
- Universidade Federal Fluminense (BR)
- AdventHealth Orlando (US)
- Hospital Israelita Albert Einstein (BR)
- Santa Casa Hospital (BR)
- AdventHealth East Orlando (US)
- WinnMed (US)
- Instituto Federal Fluminense (BR)
- Mayo Clinic in Arizona (US)
- Mayo Clinic Hospital (US)
- Universidade do Oeste de Santa Catarina (BR)
- Mayo Clinic in Florida (US)
- Institut Paoli-Calmettes (FR)
- University of Virginia (US)
Publication Details
- Journal
- ESMO Open
- Published
- 2026-02-12
- DOI
- https://doi.org/10.1016/j.esmoop.2026.106066
- Primary Topic
- Gastric Cancer Management and Outcomes
- Type
- article
- Field-Weighted Citation Impact
- 0.00